Treatment IND: how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What Treatment IND is

Origin and authorising body. United States Food and Drug Administration, 21 CFR 312.320 (treatment IND or treatment protocol). The authorising body for each individual case is the United States Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER), with parallel destination-country regulator review for cross-border enrolment, acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. 21 CFR 312.320 authorises a treatment IND or treatment protocol for widespread use of a promising investigational drug late in development, where the drug is intended to treat a serious or immediately life-threatening disease in patients who lack satisfactory alternatives, the drug is being studied in a controlled clinical trial under an IND or all clinical trials have been completed, and the sponsor is actively pursuing marketing approval.

Treatment IND is the third and broadest tier of FDA Expanded Access. Unlike a Single Patient IND (one named patient) or an intermediate-size IND (a defined group), Treatment IND authorises supply to a large population of patients who meet defined eligibility criteria. The framework is reserved for drugs late in development with substantial safety and efficacy data already generated through controlled trials, where the manufacturer is actively pursuing full marketing approval but the patient population's clinical need cannot wait. Treatment IND functions as a bridge between Phase 3 completion and full FDA approval.

Because Treatment IND covers a population rather than an individual, it requires a full written protocol with defined eligibility criteria, monitoring plans, and adverse-event reporting. The IRB at each participating site reviews the protocol locally. Cost recovery under 21 CFR 312.8 is permitted, and some Treatment INDs operate as cost-recovery programmes while others provide the drug free. For cross-border patients, a Treatment IND on the US side typically pairs with a destination-country compassionate-use or named-patient permit. The FDA review for a new Treatment IND runs on standard IND review timelines (30 days for initial review, longer for protocol amendments).

This page consolidates Reserve Meds's operational view of the Treatment IND framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Treatment IND-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use Treatment IND

Treatment IND is used when the patient population is large enough that individual Single Patient INDs would be impractical, when the manufacturer is willing to sponsor a broad pre-approval access programme, and when the drug is late enough in development that supporting safety and efficacy data are substantial. Cross-border patients can access a Treatment IND if the manufacturer's programme accepts international enrolment and if the destination country grants a parallel named-patient or compassionate-use permit. Eligibility is defined by the protocol, not by individual clinical judgment, although the treating physician confirms the patient meets the protocol criteria.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under Treatment IND

Late-Phase 3 oncology agents awaiting FDA approval, post-Phase 3 rare-disease therapies in pre-approval limbo, antivirals in development for emerging pathogens, paediatric formulations completing dedicated paediatric studies, and combination regimens in late development.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Treatment IND import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Treatment IND framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Treatment IND dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Treatment IND clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Treatment IND authorisation as the legal basis for import but does recognise a Treatment IND authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A Treatment IND application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Treatment protocol with defined eligibility criteria, dosing, monitoring, and adverse event reporting plan.
• Manufacturer-held Treatment IND (the physician enrols patients under the existing protocol rather than filing a new IND).
• Patient clinical history confirming eligibility per the protocol.
• Informed consent specific to the Treatment IND protocol.
• Local IRB review and approval at the dispensing site.
• For cross-border supply: destination-country named-patient or compassionate-use application running in parallel.

Typical timeline

Once the Treatment IND is open and the patient meets eligibility, enrolment can be rapid: the IRB review at the dispensing site typically clears within 2 to 4 weeks, the destination-country named-patient permit runs 5 to 25 business days, and shipment follows immediately upon both clearances. End-to-end, most patients can complete enrolment and receive the first dose within 4 to 6 weeks of initial referral.

Costs and reimbursement

Cost recovery under 21 CFR 312.8 is permitted but not automatic. Some manufacturers provide Treatment IND medicines free during the pre-approval access window as a managed-access policy; others charge a cost-recovery price. International logistics, customs, dispensing handling, and coordinator fees apply as for any cross-border supply. Insurer reimbursement is uncommon during pre-approval access.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Treatment IND cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Treatment IND framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works